DNA vs INCY
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Sep 22, 2026
DNA
INCY
Investment Advisor Scores
INCY
AI Analyst Insights
Detailed Metrics Comparison
| Metric | DNA | INCY | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 0 | 14.5349 | Tie |
| PEG Ratio | 0 | 10.8221 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | -48.5% | 37.7% | INCY |
| Earnings Growth | 0.0% | 37.7% | INCY |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 48.7/100 | 58.0/100 | INCY |
| Profit Margin | -219.6% | 27.7% | INCY |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | BUY | INCY |
Relative Price Performance (Last 90 Days)
Current Technical Phase
DNA
NeutralMixed signals - no dominant trend phase, RSI 75
INCY
NeutralMixed signals - no dominant trend phase, RSI 34
Fundamentals Snapshot
| Metric | DNA | INCY |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -4.3 | 13.1 |
| Trailing P/E | — | 15.5 |
| Revenue (TTM) | — | — |
| Revenue Growth | -0.5% | 0.4% |
| Gross Margin | 0.7% | 0.6% |
| Operating Margin | -2.8% | 0.4% |
| EPS | -5.19 | 7.58 |
| Dividend Yield | — | — |